The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
FDA approves Gallium-68 DOTATOC PET/CT, another new imaging agent, for use in scanning neuroendocrine tumors. Data showed Gallium-68 DOTATOC superior to decades-old methods for disease staging, treatment planning, and identifying unknown primary sites.
New grant explores precision drug delivery in NETs The American Association of Cancer Researchers (AACR) has awarded a NETRF-funded research grant to a Texas researcher
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET
John Kanki, PhD, has joined Neuroendocrine Tumor Research Foundation (NETRF) as Director of Research. In this position, Dr. Kanki will oversee the strategic, scientific, and
UCSF Shares Promising Results of a Clinical Trial At the 2019 meeting of the American Cancer Society of Clinical Oncologists (ASCO), Emily Bergsland, MD, University
Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research Symposium on May 2-3, 2019, in Cambridge, MA. More than
NETRF Announces 2019 Neuroendocrine Cancer Research Funding Opportunities New award to fund early career investigators The Neuroendocrine Tumor Research Foundation (NETRF) has announced a new
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Increasing Precision in Cancer Cell Death to Prevent Metastasis In housework and lawn work, it is important to have the right tool for the job.